Demedetomidine and Remifentanil in Electroconvulsive Therapy (ECT)

Condition(s) studied

Investigational drug(s) / intervention(s)

Saline (0.9% NaCl): Saline will infused over 10 minutes (total volume: 30 mL)

Dexmedetomidine: Dexmedetomidine at a dose of 0.5 μg/kg will infused over 10 minutes (total volume: 30 mL)

Remifentanil: Remifentanil at a dose of 1 μg/kg will infused over 10 minutes (total 30 ml)

Study summary

Electroconvulsive therapy (ECT) is a treatment modality that induces therapeutic seizures through electrical stimulation for the management of certain psychiatric disorders. Nearly all ECT procedures are performed under general anesthesia. However, ECT is commonly associated with acute hyperdynamic responses immediately following electrical stimulation, including transient hypertension and tachycardia. These acute hemodynamic changes may pose significant risks, particularly in patients with ischemic heart disease, hypertension, or cerebrovascular disease. Therefore, the hemodynamic response, seizure quality, and recovery profile are critical factors influencing the choice of anesthetic and adjuvant agents. The primary goal of anesthesia for ECT is to maintain hemodynamic stability without compromising seizure duration or quality while ensuring rapid and safe recovery

Eligibility

Primary outcome measure(s)

• Hemodynamic response — Before administration of the study medications (t0), and at 1 (t1), 3 (t2), and 10 (t3) minutes after the seizure ended.
  Arterial blood pressure will be recorded at the following times.

Trial sites (1)

More Inonu University trials in Turkey